MGD-024

DB17265Investigational

MGD-024 is an anti-CD123/anti-CD3 bispecific DART molecule.

Mechanism: Pharmacologically active on Interleukin-3 receptor subunit alpha and T-cell surface glycoprotein CD3
Curator reviewed
Code names: MGD-024

Resolves to

Targets

What you can answer from here — as of July 08, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

1Clinical trialPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with MGD-024, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.